Tiffany Gill
Major grant funding to progress lipid-based ...
Major grant funding to progress lipid-based therapies to treat prostate cancer
Tiffany Gill
Inaugural FCMHW Early Career Research Fellow at ...
Inaugural FCMHW Early Career Research Fellow at Flinders University - Jasmine Petersen
Tiffany Gill
Congratulations 2022 Honours Scholarship ...

Congratulations to the Centre’s 2022 Honours students on their scholarship awards and we wish them all the best for their research and training

Congratulations 2022 Honours Scholarship awardees
Publications, media release, Feature publication
Kelsey Long
Validation of a short form Male Depression Risk ...

Validation of the Male Depression Risk Scale short form in a cross-sectional study of Australian men. Herreen D, Rice S, Zajac I. Brief assessment of male depression in clinical care:BMJ Open. 2022 Mar 28;12(3):e053650. doi: 10.1136/bmjopen-2021-053650.

Contact: Dr Ian Zajac

Validation of a short form Male Depression Risk Scale
Kelsey Long
The Women of the FCMHW - International Women's ...

To celebrate International Women’s Day, the Centre is highlighting some of the fantastic women of men’s health that have been supported by the Centre and are achieving great work in the field. FCMHW encourages and commends the involvement of women in men’s health and hopes to further support it in the future.

The Women of the FCMHW - International Women's Day

androgen receptor

An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.

An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.

An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.
Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, Karaoğlanoğlu F, Omur ME, Kim S, Kobelev M, Kumar S, Sivak O, Bostock C, Bishop J, Hoogstraat M, Talal A, Stelloo S, van der Poel H, Bergman AM, Ahmed M, Fazli L, Huang H, Tilley W, Goodrich D, Feng FY, Gleave M, He HH, Hach F, Zwart W, Beltran H, Selth L, Zoubeidi A.
Nat Cell Biol. 2021 Sep;23(9):1023-1034. doi: 10.1038/s41556-021-00743-5. Epub 2021 Sep 6.PMID: 34489572
Contact: Luke Selth

The androgen receptor: A promising treatment for breast cancer

The androgen receptor: A promising treatment for breast cancer

The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer
Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D, Jindal S, Hui M, Finlay-Schultz J, Ebrahimie E, Birrell SN, Stelloo S, Iggo R, Alexandrou S, Caldon CE, Abdel-Fatah TM, Ellis IO, Zwart W, Palmieri C, Sartorius CA, Swarbrick A, Lim E, Carroll JS, Tilley WD. Nat Med. 2021 Jan 18. doi: 10.1038/s41591-020-01168-7.
Contact: Wayne Tilley

Investigating the effects of androgen therapies on the prostate immune system

Investigating the effects of androgen therapies on the prostate immune system

Immunotherapy approaches for prostate cancer have been largely unsuccessful, despite many clinical trials. We propose that harnessing the immune system to treat prostate cancer first requires a better understanding of the unique biology of this disease. The objective of this research program is to investigate the interplay between androgen receptor signalling and immunity in prostate cancer

Contact: A/Prof Luke Selth

Androgen receptor (AR) signalling and drug resistance in prostate cancer

Androgen receptor (AR) signalling and drug resistance in prostate cancer

The androgen receptor (AR) is a key protein in prostate cells that binds androgen sex hormones (e.g. testosterone) that drive prostate cancer development and progression. We are leading research developing and trialling new androgen receptor targeted drugs to combat drug resistance and fatal disease.

The University of Adelaide
Contact: Professor Lisa Butler, Associate Professor Luke Selth